ISRCTN99599132 https://doi.org/10.1186/ISRCTN99599132

Study to evaluate the efficacy, safety and tolerability of pumactant 240mg in the prevention of the formation of peritoneal adhesions following abdominal surgery

Submission date
18/02/2011

Registration date
31/03/2011

Last Edited
13/03/2014

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Surgery

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Sami Shimi

Contact details
Department of Surgery
University of Dundee
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY

Additional identifiers

Protocol serial number
8

Study information

Scientific Title

A randomised, partially double-blind, controlled, parallel group study to evaluate the efficacy, safety and tolerability of pumactant 240mg in the prevention of the formation of peritoneal adhesions following abdominal surgery

Study objectives
It is hypothesised that the application of pumactant powder into the abdominal cavity of human subjects following abdominal surgery may significantly reduce adhesion formation and potentially their associated morbidity. This trial was carried out to evaluate the efficacy of pumactant in reducing the formation of new peritoneal adhesions or the reformation of adhesions following abdominal surgery and its safety.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Tayside Committee on Medical Research Ethics, approved in February 2000.
At the time COREC identified Aberdeen Ethics committee as the Main REC (MREC) for this study. This was communicated and became effective from August 2004.

Study design
Randomised partially double-blind controlled parallel group multi-centre study

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Post operative intraperitoneal adhesions

Interventions
On completion of the first surgical procedure for each subject, the peritoneum was cleansed and irrigated with saline. A single dose of pumactant powder 240 mg (comprising of 3 puffer devices administering 80 mg per device) was administered (according to the randomisation schedule) to the peritoneal surface as an airborne dispersion immediately prior to closure. This was puffed onto the surface of the peritoneal cavity via carbon dioxide (CO2), using a puffer device, in as even strokes as possible so as to obtain a uniform covering.

For subjects randomised to receive CO2 alone (placebo), the identical puffer device was used but this was loaded with an empty vial (i.e. it administered only CO2 into the peritoneal cavity). After recovery from surgery, patients were readmitted 3-6 months later for reversal of colostomy / ileostomy. At that stage, adhesions were assessed and a further dose of pumactant (240 mg) or placebo was administered into the peritoneal cavity. After discharge from the second surgery, the patients involvement in the trial ceased.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Pumactant

Primary outcome(s)
The evaluation of the efficacy of pumactant 240 mg in reducing the formation of peritoneal adhesions following abdominal surgery

Key secondary outcome(s))
Evaluate the safety and tolerability of pumactant 240 mg used in the peritoneal cavity following abdominal surgery

Completion date
01/07/2005

Eligibility

Key inclusion criteria
1. Male and female subjects (> 18 years old) were recruited into the study if it was thought that at the primary surgical procedure, they required the formation of a temporary stoma
2. Patients undergoing emergency treatment of obstructed /perforated carcinoma of the bowel or colonic diverticulitis by Hartmanns procedure
3. Patients undergoing elective low anterior bowel resection for the treatment of rectal carcinoma requiring formation of a temporary ileostomy

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
All

Key exclusion criteria
1. Patients unable to comply with the study requirements, had cognitive impairments, had a history of drug and / or alcohol abuse
2. Patients receiving steroid medication
3. Patients had metastatic disease
4. Patients had American Society of Anesthesiologists (ASA) fitness grade of IV or above
5. Pregnant or lactating females

Date of first enrolment
01/04/2001

Date of final enrolment
01/07/2005

Locations

Countries of recruitment
United Kingdom

Scotland

Study participating centre
Department of Surgery
Dundee
United Kingdom
DD1 9SY

Sponsor information

Organisation
Research and Innovation Service, University of Dundee (UK)

ROR
https://ror.org/03h2bxq36

Funder(s)

Funder type
Industry

Funder Name
Britannia Pharmaceuticals Limited, Surrey (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2012		Yes	No